Drug profile · INN
etanercept
BRENZYS
etanercept (BRENZYS) is a tnf-alpha inhibitor. Associated with Pfizer Australia Pty Ltd. Route of administration: subcutaneous. Current US regulatory status: approved.
Drug details — etanercept
- US status
- approved
- Class
- Antineoplastic and immunomodulating agents (L04)
- Route
- SUBCUTANEOUS
- Patents
- 20
- Programs
- 20
- Data quality
- 0.84
Quick answer
etanercept (BRENZYS) is a tnf-alpha inhibitor. Associated with Pfizer Australia Pty Ltd. Route of administration: subcutaneous. Current US regulatory status: approved.
Key facts
Mechanism of action
TNF-alpha inhibitor
Primary target: Tumor necrosis factor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
| TGA | approved | — |
Recent coverage
Pipeline programs
Related & competitor drugs
Related patents
-
US 11419812
Methods for delivering etanercept preparations into a lumen of the intestinal tract using a swallowable drug delivery device
granted -
US 11135267
Etanercept formulations stabilized with metal ions
granted -
US 11129876
Etanercept formulations stabilized with amino acids
granted -
US 11001627
Correctly folded etanercept in high purity and excellent yield
granted -
US 11000588
Etanercept formulations stabilized with sodium chloride
granted -
US 10987405
Method of reducing formation of etanercept aggregates or fragments
granted -
US 10980885
Method of reducing formation of etanercept aggregates or fragments
granted -
US 10980884
Stable aqueous etanercept composition
granted -
US 10975138
Correctly folded etanercept composition
granted -
US 10954293
Correctly folded etanercept in high purity and excellent yield
granted -
US 10954294
Correctly folded etanercept in high purity and excellent yield
granted -
US 10954295
Correctly folded etanercept in high purity and excellent yield
granted -
US 10947306
Correctly folded etanercept in high purity and excellent yield
granted -
US 10888619
Stable aqueous etanercept composition
granted -
US 10822429
Etanercept formulations exhibiting marked reduction in sub-visible particles
granted -
US 10772963
Etanercept formulations stabilized with xylitol
granted -
US 10639272
Methods for delivering etanercept preparations into a lumen of the intestinal tract using a swallowable drug delivery device
granted -
US 10493151
Etanercept formulations stabilized with sodium chloride
granted -
US 10485869
Etanercept formulations stabilized with meglumine
granted -
US 10376588
Etanercept formulations stabilized with combinations of sugars and polyols
granted
Frequently asked questions
What is etanercept?
etanercept (BRENZYS) is a tnf-alpha inhibitor. Associated with Pfizer Australia Pty Ltd. Route of administration: subcutaneous. Current US regulatory status: approved.
What is the brand name for etanercept?
BRENZYS is a marketed brand name for etanercept. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of etanercept?
etanercept has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.